Third-Quarter Net Income of
Q3 FY26 net sales increase led by a 9.7% YoY increase in PMT net sales
Total backlog at
LAFOX, Ill.,
“I am pleased to report that
“As we look ahead, our backlog now stands at its highest level in nearly three years, providing us with confidence in our future growth outlook. We are seeing sustained demand across key end markets, particularly in power management, energy transition, and semiconductor applications, and we believe our focused investments in engineering, product development, and customer engagement are positioning us to capitalize on these opportunities. With a strengthened pipeline, strong balance sheet, and improving order trends, we remain confident in our ability to drive continued growth and deliver long-term value for our shareholders,”
Third Quarter Results
Net sales for the third quarter of fiscal 2026 were
Year-over-year net sales growth was due to higher sales in PMT. PMT sales increased due to strong growth in semi-conductor wafer fab and RF and Microwave products. Since the
Backlog grew 11.4% to
Gross margin for the third quarter was 31.9% of net sales, compared to 31.0% during the third quarter of fiscal 2025. PMT gross margin increased to 32.1%, compared to 29.9%, as a result of product mix and lower manufacturing under absorption. GES gross margin decreased to 30.8%, from 32.8% due to product mix. Canvys gross margin decreased to 32.2%, from 33.2% primarily due to unfavorable manufacturing absorption and higher freight costs.
Operating expenses were
Operating income was
Income tax provision was
Net income was
EBITDA* was
The Company maintained its solid financial position with cash and cash equivalents of
As of the end of the third quarter of fiscal 2026, the Company had no outstanding debt on its revolving line of credit with PNC Bank.
Financial Summary for the Nine Months Ended
- Net sales for the first nine months of fiscal 2026 were
$162.4 million , an increase of 3.4%, compared to net sales of$157.0 million during the first nine months of fiscal 2025. When excluding Healthcare, net sales increased 7.2% year-over-year. Sales increased by$3.0 million or 2.8% for PMT,$1.0 million or 4.3% for GES and$1.3 million or 5.6% for Canvys. When excluding Healthcare net sales, PMT net sales increased 8.2%. - Gross profit increased to
$50.7 million during the first nine months of fiscal 2026, compared to$48.4 million during the first nine months of fiscal 2025. As a percentage of net sales, gross margin improved to 31.2% of net sales during the first nine months of fiscal 2026, compared to 30.8% during the first nine months of fiscal 2025. - Operating expenses increased to
$48.1 million for the first nine months of fiscal 2026, compared to$46.6 million for the first nine months of fiscal 2025. As a percentage of net sales, operating expenses were 29.6% in the first nine months of fiscal 2026 versus 29.7% in the prior year’s first nine months. The increase in operating expenses resulted primarily from higher salaries, incentive and legal expenses. - Operating income during the first nine months of fiscal 2026 was
$2.6 million , compared to an operating loss of$3.1 million and non-GAAP operating income* of$1.8 million during the first nine months of fiscal 2025. - Other income, for the first nine months of fiscal 2026, including interest income, foreign exchange, and other, was
$0.7 million , as compared to other expense of$0.4 million in the first nine months of fiscal 2025. The increase from the prior year’s first nine months was mainly due to a non-recurring gain of$0.9 million . - The income tax provision was
$0.6 million for the first nine months of fiscal 2026 compared to an income tax benefit of$1.3 million and non-GAAP income tax provision* of$1,000 during the first nine months of fiscal 2025. - Net income for the first nine months of fiscal 2026 was
$2.7 million , versus a net loss of$2.2 million and non-GAAP net income* of$1.4 million during the first nine months of fiscal 2025. Earnings per common share (diluted) were$0.19 for the first nine months of fiscal 2026 compared to$0.16 net loss per common share (diluted) and non-GAAP earnings per common share* of$0.10 for the first nine months of fiscal 2025. - EBITDA* for the first nine months of fiscal 2026 was
$6.2 million versus negative$0.5 million in the prior year’s first nine months. EBITDA* after adjusting to exclude the loss on the sale of Healthcare assets (Adjusted EBITDA*) was$4.5 million in the first nine months of fiscal 2025.
* Please refer to Unaudited Reconciliation between GAAP and non-GAAP Financial Measures below for a reconciliation of non-GAAP items to the comparable GAAP measures.
CASH DIVIDEND DECLARED
The Board of Directors of
NON-GAAP FINANCIAL MEASURES
In addition to financial measures (“GAAP financial measures”) prepared in accordance with generally accepted accounting principles in
Non-GAAP Operating Income: Non-GAAP operating income is GAAP operating income (loss), adjusted to exclude a one-time loss on the sale of assets of the Company’s Healthcare business recorded in fiscal 2025. The following table represents the Company’s calculation of non-GAAP operating income for the periods presented and a reconciliation to the most directly comparable GAAP financial measure:
| Unaudited | |||||||||||||||
| ($ in thousands) | |||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| Operating income (loss) reconciliation | |||||||||||||||
| Income (loss) from operations | $ | 1,497 | $ | (2,743 | ) | $ | 2,597 | $ | (3,094 | ) | |||||
| Loss on disposal of healthcare assets and other charges | — | 4,916 | — | 4,916 | |||||||||||
| Non-GAAP operating income | $ | 1,497 | $ | 2,173 | $ | 2,597 | $ | 1,822 | |||||||
Non-GAAP Income Before Taxes: Non-GAAP Income Before Taxes is income (loss) before taxes, adjusted to exclude a one-time loss on the sale of assets of the Company’s Healthcare business recorded in fiscal 2025.The following table represents the Company’s calculation of non-GAAP Income Before Taxes for the periods presented and a reconciliation to the most directly comparable GAAP financial measure:
| Unaudited | |||||||||||||||
| ($ in thousands) | |||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| Income (loss) before income taxes reconciliation | |||||||||||||||
| Income (loss) before income taxes | $ | 1,195 | $ | (3,088 | ) | $ | 3,329 | $ | (3,495 | ) | |||||
| Loss on disposal of healthcare assets and other charges | — | 4,916 | — | 4,916 | |||||||||||
| Non-GAAP income before taxes | $ | 1,195 | $ | 1,828 | $ | 3,329 | $ | 1,421 | |||||||
NON-GAAP FINANCIAL MEASURES
(continued)
Non-GAAP Income Tax Expense or Benefit: Non-GAAP Income Tax Expense or Benefit is income tax provision (benefit), adjusted to exclude a one-time loss on the sale of assets of the Company’s Healthcare business recorded in fiscal 2025. The following table represents the Company’s calculation of non-GAAP Income Tax Expense (Benefit) for the periods presented and a reconciliation to the most directly comparable GAAP financial measure:
| Unaudited | |||||||||||||||
| ($ in thousands) | |||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| Income tax provision (benefit) reconciliation | |||||||||||||||
| Income tax provision (benefit) | $ | 302 | $ | (1,031 | ) | $ | 648 | $ | (1,277 | ) | |||||
| Loss on disposal of healthcare assets and other charges | — | 1,278 | — | 1,278 | |||||||||||
| Non-GAAP income tax provision | $ | 302 | $ | 247 | $ | 648 | $ | 1 | |||||||
Non-GAAP Net Income: Non-GAAP Net Income is net income (loss), adjusted to exclude a one-time loss on the sale of assets of the Company’s Healthcare business recorded in fiscal 2025. The following table represents the Company’s calculation of non-GAAP Net Income for the periods presented and a reconciliation to the most directly comparable GAAP financial measure:
| Unaudited | |||||||||||||||
| ($ in thousands) | |||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| Net income (loss) reconciliation | |||||||||||||||
| Net income (loss) | $ | 893 | $ | (2,057 | ) | $ | 2,681 | $ | (2,218 | ) | |||||
| Loss on disposal of healthcare assets and other charges | — | 3,638 | — | 3,638 | |||||||||||
| Non-GAAP net income | $ | 893 | $ | 1,581 | $ | 2,681 | $ | 1,420 | |||||||
Non-GAAP Earnings Per Common Share (Diluted): Non-GAAP Earnings Per Common Share (Diluted) is net income (loss) per share (diluted), adjusted to exclude a one-time loss on the sale of assets of the Company’s Healthcare business recorded in fiscal 2025. The following table represents the Company’s calculation of non-GAAP Earnings Per Common Share (diluted) for the periods presented and a reconciliation to the most directly comparable GAAP financial measure:
| Unaudited | |||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| Net income (loss) per share (diluted) reconciliation | |||||||||||||||
| Net income (loss) per share (diluted) | $ | 0.07 | $ | (0.15 | ) | $ | 0.19 | $ | (0.16 | ) | |||||
| Loss on disposal of healthcare assets and other charges | — | 0.26 | — | 0.26 | |||||||||||
| Non-GAAP net income per share (diluted) | $ | 0.07 | $ | 0.11 | $ | 0.19 | $ | 0.10 | |||||||
NON-GAAP FINANCIAL MEASURES
(continued)
EBITDA: EBITDA is net income (loss), plus income tax expense (benefit) and depreciation and amortization expense. The following table represents the Company’s calculation of EBITDA for the periods presented and a reconciliation to the most directly comparable GAAP financial measure:
| Unaudited | |||||||||||||||
| ($ in thousands) | |||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| Net income (loss) | $ | 893 | $ | (2,057 | ) | $ | 2,681 | $ | (2,218 | ) | |||||
| Income tax provision (benefit) | 302 | (1,031 | ) | 648 | (1,277 | ) | |||||||||
| Depreciation & amortization | 989 | 978 | 2,897 | 3,037 | |||||||||||
| EBITDA | $ | 2,184 | $ | (2,110 | ) | $ | 6,226 | $ | (458 | ) | |||||
Adjusted EBITDA: Adjusted EBITDA is EBITDA (a non-GAAP financial measure defined and calculated in accordance with the above), adjusted to exclude a one-time loss on the sale of assets of the Company’s Healthcare business recorded in fiscal 2025. The following table represents the Company’s calculation of Adjusted EBITDA for the periods presented and a reconciliation to the most directly comparable GAAP financial measure:
| Unaudited | |||||||||||||||
| ($ in thousands) | |||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| Net income (loss) | $ | 893 | $ | (2,057 | ) | $ | 2,681 | $ | (2,218 | ) | |||||
| Income tax provision (benefit) | 302 | (1,031 | ) | 648 | (1,277 | ) | |||||||||
| Depreciation & amortization | 989 | 978 | 2,897 | 3,037 | |||||||||||
| EBITDA | 2,184 | (2,110 | ) | 6,226 | (458 | ) | |||||||||
| Loss on disposal of healthcare assets and other charges | - | 4,916 | - | 4,916 | |||||||||||
| Adjusted EBITDA | $ | 2,184 | $ | 2,806 | $ | 6,226 | $ | 4,458 | |||||||
Management believes the non-GAAP financial measures referenced herein provide useful information to investors in assessing the Company’s financial performance because items that are not considered by the Company to be indicative of the Company’s ongoing results, such as the one-time loss on the sale of assets of the Company’s Healthcare business, are excluded.
Our management uses these non-GAAP financial measures along with the most directly comparable GAAP financial measures in evaluating our financial performance and when planning, forecasting and analyzing future periods.
The non-GAAP financial measures presented herein, as determined and presented by the Company, may not be comparable to related or similarly titled measures reported by other companies. These non-GAAP financial measures are not intended to be used as a substitute for the related GAAP financial measures. The non-GAAP financial measures should be viewed in addition to, and not as an alternative for, our reported results prepared in accordance with GAAP.
CONFERENCE CALL INFORMATION
The Company will host a conference call and question-and-answer session on
Participants may register for the call here. While not required, it is recommended you join 10 minutes prior to the event start. A replay of the call will be available beginning at
In addition, the webcast link is available here.
FORWARD-LOOKING STATEMENTS
This release includes certain “forward-looking” statements as defined by the
ABOUT
More than 55% of our products are manufactured in LaFox,
Richardson Electronics’ common stock trades on the NASDAQ Global Select Market under the ticker symbol RELL.
Consolidated Balance Sheets (in thousands, except per share amounts) | |||||||
| Unaudited | Audited | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 29,494 | $ | 35,901 | |||
| Accounts receivable, less allowance for credit losses of | 27,041 | 24,117 | |||||
| Inventories, net | 107,619 | 102,799 | |||||
| Prepaid expenses and other assets | 5,827 | 3,070 | |||||
| Total current assets | 169,981 | 165,887 | |||||
| Non-current assets: | |||||||
| Property, plant and equipment, net | 18,894 | 18,355 | |||||
| Intangible assets, net | 300 | 345 | |||||
| Right of use lease assets, net | 1,573 | 2,276 | |||||
| Deferred income tax assets | 8,709 | 8,744 | |||||
| Other non-current assets | 342 | 228 | |||||
| Total non-current assets | 29,818 | 29,948 | |||||
| Total assets | $ | 199,799 | $ | 195,835 | |||
| Liabilities and Stockholders' Equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 23,010 | $ | 21,339 | |||
| Accrued liabilities | 13,872 | 14,276 | |||||
| Lease liabilities current | 938 | 1,171 | |||||
| Total current liabilities | 37,820 | 36,786 | |||||
| Non-current liabilities: | |||||||
| Deferred income tax liabilities | 84 | 81 | |||||
| Lease liabilities non-current | 635 | 1,105 | |||||
| Other non-current liabilities | 1,110 | 1,204 | |||||
| Total non-current liabilities | 1,829 | 2,390 | |||||
| Total liabilities | 39,649 | 39,176 | |||||
| Commitments and contingencies | |||||||
| Stockholders’ Equity | |||||||
| Common stock, and outstanding on | 625 | 618 | |||||
| Class B common stock, convertible, issued and outstanding on respectively | 102 | 102 | |||||
| Additional paid-in-capital | 76,088 | 74,445 | |||||
| Retained earnings | 79,446 | 79,340 | |||||
| Accumulated other comprehensive income | 3,889 | 2,154 | |||||
| Total stockholders' equity | 160,150 | 156,659 | |||||
| Total liabilities and stockholders’ equity | $ | 199,799 | $ | 195,835 | |||
Unaudited Consolidated Statements of Comprehensive Income (Loss) (in thousands, except per share amounts) | |||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| Net sales | $ | 55,472 | $ | 53,804 | $ | 162,367 | $ | 157,020 | |||||||
| Cost of sales | 37,792 | 37,131 | 111,681 | 108,595 | |||||||||||
| Gross profit | 17,680 | 16,673 | 50,686 | 48,425 | |||||||||||
| Selling, general and administrative expenses | 16,176 | 14,500 | 48,079 | 46,607 | |||||||||||
| Loss (gain) on disposal of property, plant and equipment | 7 | — | 10 | (4 | ) | ||||||||||
| Loss on disposal of healthcare assets and related charges | — | 4,916 | — | 4,916 | |||||||||||
| Operating income (loss) | 1,497 | (2,743 | ) | 2,597 | (3,094 | ) | |||||||||
| Other (expense) income: | |||||||||||||||
| Interest income | 122 | 84 | 436 | 187 | |||||||||||
| Foreign exchange loss | (437 | ) | (456 | ) | (627 | ) | (616 | ) | |||||||
| Other, net | 13 | 27 | 923 | 28 | |||||||||||
| Total other (expense) income | (302 | ) | (345 | ) | 732 | (401 | ) | ||||||||
| Income (loss) before income taxes | 1,195 | (3,088 | ) | 3,329 | (3,495 | ) | |||||||||
| Income tax provision (benefit) | 302 | (1,031 | ) | 648 | (1,277 | ) | |||||||||
| Net income (loss) | 893 | (2,057 | ) | 2,681 | (2,218 | ) | |||||||||
| Foreign currency translation gain (loss), net of tax | 1,072 | (702 | ) | 1,735 | (1,814 | ) | |||||||||
| Comprehensive income (loss) | $ | 1,965 | $ | (2,759 | ) | $ | 4,416 | $ | (4,032 | ) | |||||
| Net income (loss) per share: | |||||||||||||||
| Common stock - Basic | $ | 0.07 | $ | (0.15 | ) | $ | 0.19 | $ | (0.16 | ) | |||||
| Class B common stock - Basic | 0.06 | (0.13 | ) | 0.17 | (0.14 | ) | |||||||||
| Common stock - Diluted | 0.07 | (0.15 | ) | 0.19 | (0.16 | ) | |||||||||
| Class B common stock - Diluted | 0.06 | (0.13 | ) | 0.17 | (0.14 | ) | |||||||||
| Weighted average number of shares: | |||||||||||||||
| Common stock – Basic | 12,493 | 12,333 | 12,455 | 12,283 | |||||||||||
| Class B common stock – Basic | 2,037 | 2,049 | 2,044 | 2,049 | |||||||||||
| Common stock – Diluted | 12,696 | 12,333 | 12,628 | 12,283 | |||||||||||
| Class B common stock – Diluted | 2,037 | 2,049 | 2,044 | 2,049 | |||||||||||
Unaudited Consolidated Statements of Cash Flows (in thousands) | |||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| Operating activities: | |||||||||||||||
| Net income (loss) | $ | 893 | $ | (2,057 | ) | $ | 2,681 | $ | (2,218 | ) | |||||
| Adjustments to reconcile net income to cash (used in) provided by operating activities: | |||||||||||||||
| Unrealized foreign currency loss (gain) | (257 | ) | 456 | (421 | ) | 429 | |||||||||
| Depreciation and amortization | 989 | 978 | 2,897 | 3,037 | |||||||||||
| Inventory provisions | 135 | 123 | 314 | 346 | |||||||||||
| Share-based compensation expense | 330 | 320 | 1,296 | 1,226 | |||||||||||
| Loss (gain) on disposal of property, plant and equipment | 7 | — | 10 | (4 | ) | ||||||||||
| Deferred income taxes | — | (3 | ) | 36 | (82 | ) | |||||||||
| Loss on disposal of healthcare assets and related charges | — | 4,916 | — | 4,916 | |||||||||||
| Change in assets and liabilities: | |||||||||||||||
| Accounts receivable | 642 | (333 | ) | (2,532 | ) | (1,470 | ) | ||||||||
| Inventories | (1,506 | ) | 2,873 | (2,999 | ) | 1,132 | |||||||||
| Prepaid expenses and other assets | 46 | (382 | ) | (2,875 | ) | (344 | ) | ||||||||
| Accounts payable | (682 | ) | 2,585 | 1,406 | 7,249 | ||||||||||
| Accrued liabilities | (2,924 | ) | (4,661 | ) | (563 | ) | (4,115 | ) | |||||||
| Other | (323 | ) | (214 | ) | (632 | ) | 376 | ||||||||
| Net cash (used in) provided by operating activities | (2,650 | ) | 4,601 | (1,382 | ) | 10,478 | |||||||||
| Investing activities: | |||||||||||||||
| Capital expenditures | (759 | ) | (549 | ) | (3,390 | ) | (1,992 | ) | |||||||
| Proceeds from sale of property, plant and equipment | — | — | — | 7 | |||||||||||
| Proceeds from disposal of Healthcare assets | — | 6,985 | — | 6,985 | |||||||||||
| Net cash (used in) provided by investing activities | (759 | ) | 6,436 | (3,390 | ) | 5,000 | |||||||||
| Financing activities: | |||||||||||||||
| Proceeds from issuance of common stock | 239 | — | 453 | 307 | |||||||||||
| Cash dividends paid on common and Class B common stock | (859 | ) | (852 | ) | (2,575 | ) | (2,555 | ) | |||||||
| Proceeds from revolving credit facility | — | — | — | 1,000 | |||||||||||
| Repayment of revolving credit facility | — | — | — | (1,000 | ) | ||||||||||
| Other | — | — | (99 | ) | (159 | ) | |||||||||
| Net cash used in by financing activities | (620 | ) | (852 | ) | (2,221 | ) | (2,407 | ) | |||||||
| Effect of exchange rate changes on cash and cash equivalents | 385 | (145 | ) | 586 | (659 | ) | |||||||||
| (Decrease) increase in cash and cash equivalents | (3,644 | ) | 10,040 | (6,407 | ) | 12,412 | |||||||||
| Cash and cash equivalents at beginning of period | 33,138 | 26,635 | 35,901 | 24,263 | |||||||||||
| Cash and cash equivalents at end of period | $ | 29,494 | $ | 36,675 | $ | 29,494 | $ | 36,675 | |||||||
Unaudited Net Sales and Gross Profit
For the Third Quarter and First Nine Months of Fiscal 2026 and 2025
($ in thousands)
By Strategic Business Unit
| Three Months Ended | FY26 vs. FY25 | |||||||||
| % Change | ||||||||||
| PMT | $ | 38,726 | $ | 35,310 | 9.7 | % | ||||
| GES | 8,795 | 9,299 | -5.4 | % | ||||||
| Canvys | 7,951 | 9,195 | -13.5 | % | ||||||
| Total | $ | 55,472 | $ | 53,804 | 3.1 | % | ||||
| Nine Months Ended | FY26 vs. FY25 | |||||||||
| % Change | ||||||||||
| PMT | $ | 113,003 | $ | 109,977 | 2.8 | % | ||||
| GES | 24,359 | 23,359 | 4.3 | % | ||||||
| Canvys | 25,005 | 23,684 | 5.6 | % | ||||||
| Total | $ | 162,367 | $ | 157,020 | 3.4 | % | ||||
Gross Profit
| Three Months Ended | |||||||||||||
| % of Net Sales | % of Net Sales | ||||||||||||
| PMT | $ | 12,412 | 32.1 | % | $ | 10,568 | 29.9 | % | |||||
| GES | 2,711 | 30.8 | % | 3,049 | 32.8 | % | |||||||
| Canvys | 2,557 | 32.2 | % | 3,056 | 33.2 | % | |||||||
| Total | $ | 17,680 | 31.9 | % | $ | 16,673 | 31.0 | % | |||||
| Nine Months Ended | |||||||||||||
| % of Net Sales | % of Net Sales | ||||||||||||
| PMT | $ | 35,336 | 31.3 | % | $ | 33,240 | 30.2 | % | |||||
| GES | 7,375 | 30.3 | % | 7,337 | 31.4 | % | |||||||
| Canvys | 7,975 | 31.9 | % | 7,848 | 33.1 | % | |||||||
| Total | $ | 50,686 | 31.2 | % | $ | 48,425 | 30.8 | % | |||||
Unaudited Reconciliation Between GAAP and Non-GAAP Financial Measures For the Third Quarter and First Nine Months of Fiscal 2026 and 2025 ($ in thousands) | |||||||||||||||
| NON-GAAP INCOME (LOSS) | |||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| Operating income (loss) reconciliation | |||||||||||||||
| Income (loss) from operations | $ | 1,497 | $ | (2,743 | ) | $ | 2,597 | $ | (3,094 | ) | |||||
| Loss on disposal of healthcare assets and other charges | — | 4,916 | — | 4,916 | |||||||||||
| Non-GAAP operating income | $ | 1,497 | $ | 2,173 | $ | 2,597 | $ | 1,822 | |||||||
| Income (loss) before income taxes reconciliation | |||||||||||||||
| Income (loss) before income taxes | $ | 1,195 | $ | (3,088 | ) | $ | 3,329 | $ | (3,495 | ) | |||||
| Loss on disposal of healthcare assets and other charges | — | 4,916 | — | 4,916 | |||||||||||
| Non-GAAP income before taxes | $ | 1,195 | $ | 1,828 | $ | 3,329 | $ | 1,421 | |||||||
| Income tax provision (benefit) reconciliation | |||||||||||||||
| Income tax provision (benefit) | $ | 302 | $ | (1,031 | ) | $ | 648 | $ | (1,277 | ) | |||||
| Loss on disposal of healthcare assets and other charges | — | 1,278 | — | 1,278 | |||||||||||
| Non-GAAP income tax provision | $ | 302 | $ | 247 | $ | 648 | $ | 1 | |||||||
| Net income (loss) reconciliation | |||||||||||||||
| Net income (loss) | $ | 893 | $ | (2,057 | ) | $ | 2,681 | $ | (2,218 | ) | |||||
| Loss on disposal of healthcare assets and other charges | — | 3,638 | — | 3,638 | |||||||||||
| Non-GAAP net income | $ | 893 | $ | 1,581 | $ | 2,681 | $ | 1,420 | |||||||
| Net income (loss) per share (diluted) reconciliation | |||||||||||||||
| Net income (loss) per share (diluted) | $ | 0.07 | $ | (0.15 | ) | $ | 0.19 | $ | (0.16 | ) | |||||
| Loss on disposal of healthcare assets and other charges | — | 0.26 | — | 0.26 | |||||||||||
| Non-GAAP net income per share (diluted) | $ | 0.07 | $ | 0.11 | $ | 0.19 | $ | 0.10 | |||||||
| EBITDA | |||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| Net income (loss) | $ | 893 | $ | (2,057 | ) | $ | 2,681 | $ | (2,218 | ) | |||||
| Income tax provision (benefit) | 302 | (1,031 | ) | 648 | (1,277 | ) | |||||||||
| Depreciation & amortization | 989 | 978 | 2,897 | 3,037 | |||||||||||
| EBITDA | 2,184 | (2,110 | ) | 6,226 | (458 | ) | |||||||||
| Loss on disposal of healthcare assets and other charges | — | 4,916 | — | 4,916 | |||||||||||
| Adjusted EBITDA | $ | 2,184 | $ | 2,806 | $ | 6,226 | $ | 4,458 | |||||||
| For Details Contact: | 40W267 | |
| PO BOX 393 | ||
| Chairman and CEO | EVP & CFO | LaFox, IL 60147-0393 |
| Phone: (630) 208-2320 | (630) 208-2203 | (630) 208-2200 | Fax: (630) 208-2550 |
